Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

"Opal is an all-in-one digital platform that offers faster, more convenient ordering of Bausch + Lomb products, helping to save staff time, boost patient loyalty and reduce the administrative burden ...

Bausch & Lomb (NYSE:BLCO) may be worth around $28 a share in a potential takeover after reports that the eye care company is ...

Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from ...

The Opal platform offers eye care professionals a complementary tool for patients, featuring order tracking, appointment ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Investing.com -- Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from parent company Bausch Health, which is burdened with ...

(Bloomberg) -- Bausch + Lomb Corp. shares rose the most ever following a report that the eye-care company is considering selling itself to disentangle from its debt-laden parent company.

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Bausch + Lomb, one of the world’s largest contact lens suppliers, is exploring a sale as a way to clean ...

As part of the deal, Bausch + Lomb will help scale commercialization of Trukera’s ScoutPro Osmolarity System, a device that measures tear osmolarity, or the salt content of a person’s tears, to help ...